VERU - ベル (Veru Inc.)

VERUのニュース

   Analyzing Veru (NASDAQ:VERU) & Atossa Therapeutics (NASDAQ:ATOS)  2021/03/11 11:14:41 Modern Readers
Atossa Therapeutics (NASDAQ:ATOS) and Veru (NASDAQ:VERU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends. Volatility & Risk Atossa Therapeutics has a beta of 2.34, suggesting that its share price is […]
   Veru to Participate in Fireside Chat at the H.C. Wainwright Global Life Sciences Conference  2021/03/02 13:30:00 Yahoo Finance
MIAMI, March 02, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright Global Life Sciences Conference. The fireside chat will be available on-demand through the Conference on March 9th, 2021 starting at 7 a.m. ET. The fireside chat will also be available at https://verupharma.com/investors. The webcast will be archived and accessible on the web site for at least 90 days. About Veru Inc.Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline includes VERU-111, VERU-100, and Zuclomiphene citrate. VERU-111 is an oral, first-in-class, new chemical entity that targets, crosslinks, and disrupts alpha and beta tubulin subunits of microtubules for the treatment of metastatic castration and androgen receptor resistant prostate cancer.
   Veru Raises $100M Via Equity At 10% Discount - Stocks News Feed  2021/02/18 10:25:27 Stocks News Feed
Veru Inc (NASDAQ: VERU) priced its underwritten public offering of 6.5 million shares at $15.50 per share, with gross proceeds of approximately $100 million. Underwriters have an option to purchase up to an additional 967,741 shares. The offer price represents a discount of 10% from the last close price of $17.21 on Wednesday. Jefferies is acting as the sole… Read More »Veru Raises $100M Via Equity At 10% Discount
   Veru Raises $100M Via Equity At 10% Discount  2021/02/18 05:25:00 Benzinga
Veru Inc (NASDAQ: VERU) priced its underwritten public offering of 6.5 million shares at $15.50 per share, with gross proceeds of …
   Veru Announces Pricing of Public Offering of Common Stock  2021/02/18 02:30:00 GlobeNewswire
MIAMI, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for…
   Analyzing Veru (NASDAQ:VERU) & Atossa Therapeutics (NASDAQ:ATOS)  2021/03/11 11:14:41 Modern Readers
Atossa Therapeutics (NASDAQ:ATOS) and Veru (NASDAQ:VERU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends. Volatility & Risk Atossa Therapeutics has a beta of 2.34, suggesting that its share price is […]
   Veru to Participate in Fireside Chat at the H.C. Wainwright Global Life Sciences Conference  2021/03/02 13:30:00 Yahoo Finance
MIAMI, March 02, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright Global Life Sciences Conference. The fireside chat will be available on-demand through the Conference on March 9th, 2021 starting at 7 a.m. ET. The fireside chat will also be available at https://verupharma.com/investors. The webcast will be archived and accessible on the web site for at least 90 days. About Veru Inc.Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline includes VERU-111, VERU-100, and Zuclomiphene citrate. VERU-111 is an oral, first-in-class, new chemical entity that targets, crosslinks, and disrupts alpha and beta tubulin subunits of microtubules for the treatment of metastatic castration and androgen receptor resistant prostate cancer.
   Veru Raises $100M Via Equity At 10% Discount - Stocks News Feed  2021/02/18 10:25:27 Stocks News Feed
Veru Inc (NASDAQ: VERU) priced its underwritten public offering of 6.5 million shares at $15.50 per share, with gross proceeds of approximately $100 million. Underwriters have an option to purchase up to an additional 967,741 shares. The offer price represents a discount of 10% from the last close price of $17.21 on Wednesday. Jefferies is acting as the sole… Read More »Veru Raises $100M Via Equity At 10% Discount
   Veru Raises $100M Via Equity At 10% Discount  2021/02/18 05:25:00 Benzinga
Veru Inc (NASDAQ: VERU) priced its underwritten public offering of 6.5 million shares at $15.50 per share, with gross proceeds of …
   Veru Announces Pricing of Public Offering of Common Stock  2021/02/18 02:30:00 GlobeNewswire
MIAMI, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for…
   Analyzing Veru (NASDAQ:VERU) & Atossa Therapeutics (NASDAQ:ATOS)  2021/03/11 11:14:41 Modern Readers
Atossa Therapeutics (NASDAQ:ATOS) and Veru (NASDAQ:VERU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends. Volatility & Risk Atossa Therapeutics has a beta of 2.34, suggesting that its share price is […]
   Veru to Participate in Fireside Chat at the H.C. Wainwright Global Life Sciences Conference  2021/03/02 13:30:00 Yahoo Finance
MIAMI, March 02, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright Global Life Sciences Conference. The fireside chat will be available on-demand through the Conference on March 9th, 2021 starting at 7 a.m. ET. The fireside chat will also be available at https://verupharma.com/investors. The webcast will be archived and accessible on the web site for at least 90 days. About Veru Inc.Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline includes VERU-111, VERU-100, and Zuclomiphene citrate. VERU-111 is an oral, first-in-class, new chemical entity that targets, crosslinks, and disrupts alpha and beta tubulin subunits of microtubules for the treatment of metastatic castration and androgen receptor resistant prostate cancer.
   Veru Raises $100M Via Equity At 10% Discount - Stocks News Feed  2021/02/18 10:25:27 Stocks News Feed
Veru Inc (NASDAQ: VERU) priced its underwritten public offering of 6.5 million shares at $15.50 per share, with gross proceeds of approximately $100 million. Underwriters have an option to purchase up to an additional 967,741 shares. The offer price represents a discount of 10% from the last close price of $17.21 on Wednesday. Jefferies is acting as the sole… Read More »Veru Raises $100M Via Equity At 10% Discount
   Veru Raises $100M Via Equity At 10% Discount  2021/02/18 05:25:00 Benzinga
Veru Inc (NASDAQ: VERU) priced its underwritten public offering of 6.5 million shares at $15.50 per share, with gross proceeds of …
   Veru Announces Pricing of Public Offering of Common Stock  2021/02/18 02:30:00 GlobeNewswire
MIAMI, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for…

calendar